Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACLX 
Arcellx Inc (ACLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ACLX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $113.35
1 Year Target Price $113.35
| 12 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.31% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.10B USD | Price to earnings Ratio - | 1Y Target Price 113.35 |
Price to earnings Ratio - | 1Y Target Price 113.35 | ||
Volume (30-day avg) 18 | Beta 0.31 | 52 Weeks Range 47.86 - 107.37 | Updated Date 11/7/2025 |
52 Weeks Range 47.86 - 107.37 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -777.42% |
Management Effectiveness
Return on Assets (TTM) -19.8% | Return on Equity (TTM) -42.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4160350922 | Price to Sales(TTM) 89.51 |
Enterprise Value 4160350922 | Price to Sales(TTM) 89.51 | ||
Enterprise Value to Revenue 73.02 | Enterprise Value to EBITDA -6.52 | Shares Outstanding 57822871 | Shares Floating 37338822 |
Shares Outstanding 57822871 | Shares Floating 37338822 | ||
Percent Insiders 13.36 | Percent Institutions 105.99 |
Upturn AI SWOT
Arcellx Inc
Company Overview
History and Background
Arcellx, Inc. is a clinical-stage biotechnology company focused on developing adaptive and controllable cell therapies for the treatment of patients with cancer and other incurable diseases. Founded in 2015, Arcellx has developed the D- Domains platform to engineer more effective and controllable cell therapies.
Core Business Areas
- CAR-T Therapies: Arcellx develops CAR-T cell therapies for hematologic malignancies and solid tumors.
- D-Domains Platform: Arcellx engineers its novel D-Domains platform to create controllable and adaptable cell therapies.
Leadership and Structure
Sheng Luo, PhD, is the CEO of Arcellx, Inc. The company has a board of directors and a management team responsible for strategic direction and operations.
Top Products and Market Share
Key Offerings
- CART-ddBCMA: Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma. Currently in clinical trials, and there is no market share available yet. Key competitors are CARVYKTI (JNJ), Abecma (BMS), and other emerging BCMA-targeted therapies.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by the increasing prevalence of cancer and the potential for personalized medicine.
Positioning
Arcellx aims to be a leader in cell therapy through its novel D-Domains technology, offering potentially safer and more effective treatments.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to be worth tens of billions of dollars annually. Arcellx is positioned to capture a significant share with successful clinical development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel D-Domains technology platform
- Strong preclinical and clinical data
- Experienced management team
Weaknesses
- Clinical trial execution risks
- High manufacturing costs
- Limited commercial experience
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Advancements in manufacturing technologies
Threats
- Competition from established cell therapy players
- Regulatory hurdles
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- JNJ (JNJ)
- BMS (BMY)
- Legend Biotech (LEGN)
Competitive Landscape
Arcellx differentiates itself with its D-Domains technology, potentially offering advantages in safety and efficacy compared to competitors' cell therapies. However, it faces the challenges of competing with larger, more established companies.
Growth Trajectory and Initiatives
Historical Growth: Arcellx's growth has been defined by its progress in clinical development and preclinical advancements.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of its cell therapy products. Analyst estimates vary but generally anticipate significant revenue growth in the coming years if CART-ddBCMA is approved.
Recent Initiatives: Recent initiatives include progressing clinical trials, expanding manufacturing capabilities, and pursuing strategic partnerships.
Summary
Arcellx is a clinical-stage biotech with a promising D-Domains technology. Its lead product, CART-ddBCMA, shows great potential but is still in clinical trials. The company's success depends on navigating regulatory hurdles and competition while securing funding. The stock is high risk/high reward, as the company has limited revenue and a long path to commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arcellx Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximations based on available data. Investment decisions should be made based on your own research and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcellx Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2022-02-04 | Chairman of the Board, CEO & President Mr. Rami Elghandour | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.arcellx.com |
Full time employees 163 | Website https://www.arcellx.com | ||
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.